TULIP study: Trail of Lurasidone in bipolar disorder in Pakistan

Khan, Naveed; Nasar, Amina; Bajwa, Saqib; Butt, Aisha Jawad; Azher, Afia; Mushtaq, Tehmina; Rashid, Alina; Haq, Mian Mukhtar Ul; Rasul, Ghulam; Dogar, Firasat Ali

doi:10.1016/j.sjbs.2020.11.044

Cited by 3 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of 79 eligible RCTs, 5 single-blind RCTs did not report available data for performing a meta-analysis regarding objective outcomes [ 26 – 30 ]. Two double-blind RCTs did not report any available data for performing a meta-analysis [ 31 , 32 ]. Finally, 72 double-blinded RCTs ( n = 16442, males = 50.93%, mean age = 39.55 years, mean study duration = 3.96 ± 2.39 weeks) were included with the following treatment arms (number of studies ( N )/individuals ( n )): aripiprazole (9/1205), asenapine (3/620), brexpiprazole (2/321), carbamazepine (6/305), cariprazine (3/612), chlorpromazine (1/10), endoxifen (2/55), eslicarbazepine (2/148), haloperidol (10/1023), lamotrigine (3/173), licarbazepine (1/324), lithium (20/965), olanzapine (14/1565), oxcarbazepine (1/30), paliperidone (2/542), quetiapine (5/630), risperidone (7/676), tamoxifen (2/43), topiramate (4/659), valnoctamide (1/71), valproate (14/981), verapamil (1/17), ziprasidone (3/458), and a placebo (48/5009).…”

Section: Resultsmentioning

confidence: 99%

Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials

et al. 2021

View full text Add to dashboard Cite

A systematic review and random-effects model network meta-analysis was conducted to compare the efficacy, acceptability, tolerability, and safety of pharmacological interventions for adults with acute bipolar mania. We searched PubMed, the Cochrane Library, and Embase databases for eligible studies published before March 14, 2021. Randomized controlled trials (RCTs) of oral medication monotherapy lasting ≥10 days in adults with mania were included, and studies that allowed the use of antipsychotics as a rescue medication during a trial were excluded. The primary outcomes were response to treatment (efficacy) and all-cause discontinuation (acceptability). The secondary outcomes were the improvement of mania symptoms and discontinuation due to inefficacy. Of the 79 eligible RCTs, 72 double-blind RCTs of 23 drugs and a placebo were included in the meta-analysis (mean study duration = 3.96 ± 2.39 weeks, n = 16442, mean age = 39.55 years, with 50.93% males). Compared with the placebo, aripiprazole, asenapine, carbamazepine, cariprazine, haloperidol, lithium, olanzapine, paliperidone, quetiapine, risperidone, tamoxifen, valproate, and ziprasidone outperformed response to treatment (N = 56, n = 14503); aripiprazole, olanzapine, quetiapine, and risperidone had lower all-cause discontinuation; however, topiramate had higher all-cause discontinuation (N = 70, n = 16324). Compared with the placebo, aripiprazole, asenapine, carbamazepine, cariprazine, haloperidol, lithium, olanzapine, paliperidone, quetiapine, risperidone, tamoxifen, valproate, and ziprasidone outperformed the improvement of mania symptoms (N = 61, n = 15466), and aripiprazole, asenapine, carbamazepine, cariprazine, haloperidol, lithium, olanzapine, paliperidone, quetiapine, risperidone, valproate, and ziprasidone had lower discontinuation due to inefficacy (N = 50, n = 14284). In conclusions, these antipsychotics, carbamazepine, lithium, tamoxifen, and valproate were effective for acute mania. However, only aripiprazole, olanzapine, quetiapine, and risperidone had better acceptability than the placebo.

show abstract

Section: Resultsmentioning

confidence: 99%